Though single targeting of either TIGIT was able to partially ameliorate upregulation of exhaustion markers, dual targeting of TIGIT and CD73 was necessary to elicit robust tumor control (Figs. 5–6, Supplementary Fig. 17). Here, TIGIT is linked to neoplasm.